JS006
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) [1][2].
Product Specifications
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Andrew B, et al. Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility. WO2023034336A2. 2023-03-09. |[2]JS006.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1088667-01 0.02 mg (E-Coli)
Recombinant Caenorhabditis briggsae Enolase-phosphatase E1 (CBG23332)
Ask
View Details 
MBS1088667-02 0.1 mg (E-Coli)
Recombinant Caenorhabditis briggsae Enolase-phosphatase E1 (CBG23332)
Ask
View Details 
MBS1088667-03 0.02 mg (Yeast)
Recombinant Caenorhabditis briggsae Enolase-phosphatase E1 (CBG23332)
Ask
View Details 
MBS1088667-04 0.1 mg (Yeast)
Recombinant Caenorhabditis briggsae Enolase-phosphatase E1 (CBG23332)
Ask
View Details MBS1088667-05 0.02 mg (Baculovirus)
Recombinant Caenorhabditis briggsae Enolase-phosphatase E1 (CBG23332)
Ask
View Details MBS1088667-06 0.02 mg (Mammalian-Cell)
Recombinant Caenorhabditis briggsae Enolase-phosphatase E1 (CBG23332)
Ask
View Details